Try our beta test site

A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)

This study has been terminated.
(Slow accrual)
Sponsor:
Collaborator:
Celator Pharmaceuticals
Information provided by (Responsible Party):
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT00875693
First received: April 2, 2009
Last updated: March 1, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: June 2019
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)